An additional 160,000 Australians will have access to the COVID-19 antiviral nirmatrelvir–ritonavir under new PBS eligibility criteria. 

From 1 April, those aged 60-69 with mild-to-moderate COVID-19 and one additional risk factor for severe disease — such as heart failure or residing in a remote area — will be eligible for subsidised nirmatrelvir–ritonavir (Paxlovid).